During the past 3 years, the average EPS without NRIGrowth Rate was 21.50% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 75.30% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 9.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, BioRestorative Therapies's highest 3-Year average EPS without NRI Growth Rate was 89.60% per year. The lowest was -1024.70% per year. And the median was 30.70% per year.
BioRestorative Therapies EPS (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioRestorative Therapies's EPS (Diluted)
For the Biotechnology subindustry, BioRestorative Therapies's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies's PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's PE Ratio distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
BioRestorative Therapies's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.51
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
BioRestorative Therapies EPS (Diluted) Related Terms
Thank you for viewing the detailed overview of BioRestorative Therapies's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
BioRestorative Therapies (BioRestorative Therapies) Business Description
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BRTX has been successfully added to your 